Takeda’s Future after Losing Actos Patent

In 2012, Takeda’s profit dropped 53% and net profit was down 14% in the last nine months of 2012. Why? Because medical studies have demonstrated the causal connection between Takeda’s flagship diabetes drug Actos and bladder cancer and Takeda also lost its exclusivity patent on its foundation product diabetes treatment.  Actos accounted for more than [...]